Putting patients first
WORKING WITH PATIENTS, FOR PATIENTS
Ipsen works with patients, their families, and more than 250 patient organizations around the world at a global, regional, and national level. Our key priorities are generating data and sharing experiences. We want to guarantee that patients are truly given a seat at the table when it comes to their care and the developments that Ipsen is making. We believe this kind of close collaboration and inclusion is essential to ensure we chart the right course. Our goal is to understand and respond to patients’ needs, helping them and their caregivers at different points throughout their experiences. At Ipsen, we believe in working together with patients, for patients.
Patients drive our science in Oncology, Neuroscience and Rare Disease. Being in touch with what matters to patients and their families helps us understand their needs and work together to bring meaningful improvements to their lives.
We are committed to ensuring that people living with health conditions are heard, integrating their ideas into our transformative care methods and services. We all have a part to play in this.
OUR WORK WITH PATIENT ORGANIZATIONS
It all starts with listening. At Ipsen, we enter into dialogue with the patient community as early as possible when developing new medicines. Our focus is on long-term strategic engagement and partnerships with patient organizations.
Making a difference
Ipsen is committed to working closely and inclusively with the patient community to impact medical care and patient outcomes in our focus fields of Oncology, Rare Disease and Neuroscience.
‘Get men talking’: breaking the silence around prostate cancer
Tim Batchelor, Ipsen’s Head of Global Commercial Learning & Development, candidly shares his experience of living with prostate cancer. At the age of 48, Tim was confronted with a prostate cancer diagnosis. His early detection proved pivotal, leading to successful…
Primary Biliary Cholangitis: The Power of Patient Reported Outcomes
“The important thing with PBC is to take a holistic view of it, and think ‘What are the problems we are trying to solve? The first is the risk of progression to cirrhosis, and the other is symptoms and quality…
The Liver Meeting 2023: Innovating for people living with rare liver diseases
Jennifer Schranz (Ipsen’s Global Head of Rare Diseases) attended The Liver Meeting from November 10-14, sharing key insights from her time onsite and explaining why scientific congresses are vital in helping advance innovation for patients.
Ipsen stands together to make innovation in rare disease happen
Developing innovation for people living with rare diseases is uniquely challenging. It requires all the different pieces of the puzzle– clinical viability, economic viability and the policy environment— to come together before innovation can reach patients.
Innovating for people living with primary biliary cholangitis
At Ipsen we have been focused on developing new and innovative treatments for rare diseases for many years in endocrinology, rare bone disease and more recently in rare liver disease. This focus continues to be a core part of our…
Rising to the challenge, life after stroke
Globally, stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability across the world, with approximately 1 in 4 people over the age of 25 expected to experience…
Improving post-stroke care for survivors across the globe
Stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability, with approximately 1 in 4 people over the age of 25 expected to experience a stroke at some point in their lives.
Debbie: Living Every Moment with Follicular Lymphoma
Debbie has been living with follicular lymphoma since 2011 and wants to tell her story to encourage other people to look out for the symptoms of blood cancer and to offer support and reassurance to those who have been diagnosed.
Bridging the innovation gap in rare diseases
At the latest edition of European Health Forum Gastein, Ipsen held an interactive session to raise awareness of the challenges inherent in drug development for rare and ultra-rare diseases.
PBC Awareness Month: The power of patient voices
As anyone living with Primary Biliary Cholangitis (PBC) – a rare and progressive autoimmune liver disease1 – knows, the disease can have a significant impact on a person’s day to day life and relationships.2
Making clinical trials accessible and understandable
We are committed to ensuring that all our published research is freely available to everyone. To make this happen, we work closely with the patient community to provide summaries of key clinical studies sponsored by Ipsen in easy-to-understand language, so they are not just available, but accessible to all.
Ipsen Clinical Trials
Ipsen conducts first-in-the-world clinical trials to take science forward together. Our global network of healthcare professionals helps us test new treatments and ensure their efficacy and safety by conducting clinical trials. Our aim is to create new therapies and improve upon existing ones to improve patients’ lives and health outcomes.
Our approach to responsibility
Ipsen unites all our employees behind our global commitment to doing business responsibly through Generation Ipsen – For Positive Change. This fully integrated approach is built on four pillars: Environment, Patients, People and Governance. Generation Ipsen is designed to ensure we meet patients’ needs while working in ways that are ethical, responsible and community-minded.